

June 29, 2016

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-19) COSFROVIXIMAB

PRONUNCIATION kos" froe vix' i mab

THERAPEUTIC CLAIM Treatment of Ebola virus

## CHEMICAL NAMES

1. Immunoglobulin G1, anti-(Ebola virus/Reston ebolavirus/Sudan ebolavirus/Tai Forest ebolavirus glycoprotein) (human-*Mus musculus* monoclonal c13C6-FR1 heavy chain), disulfide with human-*Mus musculus* monoclonal c13C6-FR1  $\kappa$ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(Ebola virus/Reston ebolavirus/Sudan ebolavirus/Tai Forest ebolavirus glycoprotein); chimeric *Homo sapiens-Mus musculus* monoclonal antibody:  $\gamma$ 1 heavy chain (1-452) [*Mus musculus* VH (IGHV8-8\*01 (77%) –(IGHD)-IGHJ4\*01 (93%)) [10.7.14] (1-122) -*Homo sapiens* IGHG1\*01{CH1 K97>R(219)} (123-452)] (225-213')-disulfide with  $\kappa$  light chain (1'-213') [*Mus musculus* V-kappa (IGKV6-13\*01 (95%) –IGKJ5\*01 [6.3.9] (1'-106') -*Homo sapiens* IGKC\*01 (107'-213'))] dimer (231-231":234-234")-bisdisulfide

## STRUCTURAL FORMULA

## Heavy chain

DVKLLESGGG	LVQPGGSLKL	SCAASGFSL	TSGVGVGWFR	QPSGKGLEWL	50
ALIWWDDDKY	YNPSLKSQSL	ISKDFSRNQV	FLKISNVDIA	DTATYYCARR	100
DPFGYDNAMG	YWGQTSVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSSV	VTVPSSSLGT	200
QTYICNVNHNK	PSNTKVDKRV	EPKSCDKTHT	CPPCPAPELL	GGPSVFLFPP	250
KPKDTLMISR	TPEVTCVVVD	VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	300
YNSTYRVVSV	LTVLHQDWLN	GKEYKCKVSN	KALPAIEKT	ISKAKQPRE	350
PQVYTLPPSR	DELTKNQVSL	TCLVKGFYPS	DIAVEWESNG	QPENNYKTP	400
PVLDSDSGFF	LYSKLTVDKS	RWQQGNVFC	SVMHEALHNN	YTQKSLSLSP	450
GK					452

## Light chain

DIVMTQSPLS	LSTSVGDRVS	LTCKASQNVG	TAVAWYQQKP	GQSPKLLIYS	50'
ASNRYTGVPD	RFTGSGSGTD	FRTLTISNMQS	EDLADYFCQQ	YSSYPLTFGA	100'
GTKLELRIVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYF	REAKVQWKVD	150'
NALQSGNSQE	SVTEQDSKDS	TYSLSTLTL	SKADYEKHKV	YACEVTHQGL	200'
SSPVTKSFNR	GEC				213'

## Disulfide bridges

22-97	22"-97"	23'-88'	23'''-88'''	133'-193'	133'''-193'''	149-205	149"-205"
213'-225'	213'''-225'''	231-231"	234-234"	266-326	266"-326"	372-430	372"-430"

## Glycosylation sites (N)

Asn-302 Asn-302'

## MOLECULAR FORMULA

C<sub>6448</sub>H<sub>9962</sub>N<sub>1706</sub>O<sub>2022</sub>S<sub>42</sub> (peptide)

MOLECULAR WEIGHT	145.1 kDa (peptide)
TRADEMARK	ZMapp
SPONSOR	Mapp Biopharmaceutical Inc.
CODE DESIGNATIONS	c13C6-FR1
<u>CAS</u> REGISTRY NUMBER	1792982-57-0
UNII	820C12BHRP
WHO NUMBER	10535

gbk